SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-052419
Filing Date
2023-10-06
Accepted
2023-10-06 16:31:50
Documents
13
Period of Report
2023-10-03
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Document Format Files

Seq Description Document Type Size
1 8-K onct-20231003.htm   iXBRL 8-K 54006
  Complete submission text file 0000950170-23-052419.txt   199369

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT onct-20231003_pre.xml EX-101.PRE 13506
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT onct-20231003_def.xml EX-101.DEF 13484
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT onct-20231003_lab.xml EX-101.LAB 16665
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT onct-20231003.xsd EX-101.SCH 2902
7 EXTRACTED XBRL INSTANCE DOCUMENT onct-20231003_htm.xml XML 4715
Mailing Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130
Business Address 12230 EL CAMINO REAL SUITE 230 SAN DIEGO CA 92130 (858) 434-1113
Oncternal Therapeutics, Inc. (Filer) CIK: 0001260990 (see all company filings)

IRS No.: 621715807 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-50549 | Film No.: 231314576
SIC: 2834 Pharmaceutical Preparations